A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain
NCT00661635
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Patients had required an elective, non-urgent laparoscopic cholecystectomy, as an outpatient procedure, with ASA Class I-III, with a Baseline Pain Intensity of moderate or severe on a categorical scale and ≥45 mm on a VAS (100 mm)
- Patients were able to get their first dose of study medication within 8 hours after the end of surgery
- Patients could not undergo procedures expected to produce a greater degree of surgical
trauma than the laparoscopic cholecystectomy alone, nor have acute pre-operative pain
(other than biliary colic) nor chronic pain conditions, nor uncontrolled chronic
conditions, nor cancer, nor a laboratory abnormality that the investigator considered
to contraindicate study participation
- Patient had any cognitive impairment that would, in the investigator's opinion,
preclude study participation or compliance with protocol mandated procedures
- Patient had a history of known alcohol, analgesic, or narcotic substance abuse within
the one year prior to Screening
- Patient had any laboratory abnormality at screening, that, in the opinion of the
investigator, is not due to the condition requiring surgery and is not expected to
resolve post-surgery, and would, therefore, contraindicate study participation
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Birmingham, Alabama
- Daphne, Alabama
- Fairhope, Alabama
- Mobile, Alabama
- Mobile, Alabama
- Sheffield, Alabama
- Glendale, Arizona
- Glendale, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Tucson, Arizona
- Tucson, Arizona
- Tucson, Arizona
- Anaheim, California
- Bakersfield, California
- Bakersfield, California
- Los Angeles, California
- Los Angeles, California
- Pasadena, California
- Sacramento, California
- San Jose, California
- Woodland, California
- Miami, Florida
- Miami, Florida
- Pensacola, Florida
- Blue Ridge, Georgia
- Marietta, Georgia
- Chicago, Illinois
- Maywood, Illinois
- Iowa City, Iowa
- Shreveport, Louisiana
- Baltimore, Maryland
- Germantown, Maryland
- Rockville, Maryland
- Silver Spring, Maryland
- Jackson, Mississippi
- Durham, North Carolina
- Winston-Salem, North Carolina
- Winston-Salem, North Carolina
- Oklahoma City, Oklahoma
- Allentown, Pennsylvania
- Philadelphia, Pennsylvania
- Pittsburgh, Pennsylvania
- Charleston, South Carolina
- Columbia, South Carolina
- Columbia, South Carolina
- Mt. Pleasant, South Carolina
- North Charleston, South Carolina
- Summerville, South Carolina
- Bristol, Tennessee
- Kingsport, Tennessee
- Houston, Texas
- Houston, Texas
- San Antonio, Texas
- Universal City, Texas
- Sandy, Utah
- Sandy, Utah
- West Jordan, Utah
- Norfolk, Virginia
- Suffolk, Virginia
- Renton, Washington
- Renton, Washington
- Madison, Wisconsin
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain | |||
Official Title ICMJE | A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Placebo in Patients for Treatment of Post-Surgical Pain From Laparoscopic Cholecystectomy Surgery | |||
Brief Summary | To evaluate the analgesic efficacy, general safety, and effects on health outcome measures and opioid-related symptoms of 2 valdecoxib dosing regimens compared with placebo in patients with moderate or severe pain following laparoscopic cholecystectomy surgery. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment | |||
Condition ICMJE |
| |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 490 | |||
Original Actual Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | July 2003 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 75 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00661635 | |||
Other Study ID Numbers ICMJE | VALA-0513-145 A3471085 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | March 2008 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |